In its Q2 2026 filing, Fortrea demonstrated momentum in contract awards and operational efficiency that underscore the strength of its flexible full-service, functional service provider (FSP), and hybrid models. Operating across approximately 100 countries with over 14,000 employees, the company leverages global scale, clinical research units with cGMP pharmacies, and advanced data capture technologies to enhance patient recruitment efficiency and data quality. Despite a complex regulatory environment and persistent industry risks such as patient enrollment challenges, Fortrea’s diversified therapeutic expertise and technological investments position it well within the growing CRO outsourcing market. Financially, the company maintains significant leverage but continues to generate operating cash flow to support growth initiatives.